Surgical Treatment for Sacroiliac Joint Pain

Similar documents
Original Policy Date

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY

Diagnosis and Treatment of Sacroiliac Joint Pain. Description

Diagnosis and Treatment of Sacroiliac Joint Pain

Corporate Medical Policy

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Diagnosis and Treatment of Sacroiliac Joint Pain

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Policy #: 555 Latest Review Date: October 2016

therapies such as nonsteroidal anti-inflammatory medications, acetaminophen, manipulation,

Pain has failed to respond to 3 months of conservative management, which may consist of

Corporate Medical Policy

Corporate Medical Policy

d EFFECTIVE DATE: POLICY LAST UPDATED:

Clinical Policy: Sacroiliac Joint Interventions for Pain Management

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Corporate Medical Policy

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Vertebral Axial Decompression

MEDICAL POLICY SUBJECT: SACROILIAC JOINT FUSION/STABILIZATION: OPEN AND PERCUTANEOUS METHODS EFFECTIVE DATE: 12/15/16 REVISED DATE: 02/15/18

Facet Arthroplasty. Policy Number: Last Review: 9/2018 Origination: 9/2009 Next Review: 3/2019

FEP Medical Policy Manual

Vertebral Axial Decompression

Spinal and Trigger Point Injections

Peripheral Subcutaneous Field Stimulation

Medical Affairs Policy

Clinical Policy: Sacroiliac Joint Interventions for Pain Management

5/31/2013. Disclosures. Lumbar Facet Joint Pain: Evidence. I have nothing to disclose

MEDICAL POLICY MEDICAL POLICY DETAILS POLICY STATEMENT. Page: 1 of 7

Cigna Medical Coverage Policies Musculoskeletal Sacroiliac Joint Injections

Nonsurgical Interventional Treatments for Spinal Pain Management

Sacroiliac Joint Fusion

Facet Joint Injections and Facet Joint Nerve Blocks Effective Date December 15, 2014 Original Policy Date March 16, 1988

Clinical Reference Guide

Cigna Medical Coverage Policies Musculoskeletal Sacroiliac Joint Injections

Topic: Pulsed Radiofrequency for Chronic Spinal Pain Date of Origin: April Section: Surgery Last Reviewed Date: December 2013

Dynamic Spinal Visualization and Vertebral Motion Analysis

Bioimpedance Devices for Detection and Management of Lymphedema

Guideline Number: NIA_CG_301 Last Revised Date: March 2018 Responsible Department: Clinical Operations

Clinical Policy: Facet Joint Interventions

Sacroiliac Joint Fusion

CLINICAL GUIDELINES. CMM-203 ~ Sacroiliac Joint Injections. Version 19.0 Effective August 11, 2017

Transtympanic Micropressure Applications as a Treatment of Meniere s Disease

MEDICAL POLICY SUBJECT: RADIOFREQUENCY JOINT ABLATION / DENERVATION

Facet Joint Denervation. Populations Interventions Comparators Outcomes Individuals: With suspected facet joint pain

Manipulation under Anesthesia

PERCUTANEOUS FACET JOINT DENERVATION

Corporate Medical Policy

Peripheral Subcutaneous Field Stimulation

Clinical Policy Title: Radiofrequency ablation treatment for spine pain

Corporate Medical Policy

Interventional Pain Management

To: Manuel Suarez, M.D. Medical Director Neighborhood Health Plan Management Department 5757 Plaza Dr. Cyprus, CA Mailstop: CA

Clinical Policy: Intradiscal Electrothermal Therapy; Percutaneous Intradiscal Radiofrequency Thermocoagulation Reference Number: HNCA.CP.MP.

Percutaneous Discectomy

MEDICAL POLICY SUBJECT: RADIOFREQUENCY FACET DENERVATION

Clinical Policy Title: Radiofrequency ablation treatment for spine pain

Facet Joint Denervation

Electrical Stimulation for Scoliosis

Biofeedback as a Treatment of Headache

MEDICAL POLICY STATEMENT INDIANA MEDICAID Original Issue Date Next Annual Review Effective Date 11/01/ /01/ /17/2017

Facet Joint Denervation. Description

Antigen Leukocyte Antibody Test

Corporate Medical Policy Automated Percutaneous and Endoscopic Discectomy

Original Policy Date

MP.090.MH Nerve Block, Paravertebral, Facet Joint, and SI Injections

Intracellular Micronutrient Analysis

Medical Policy Facet Joint Denervation. Effective Date February 15, Subsection. 7.0 Surgery. Next Review Date December 2015

Lysis of Epidural Adhesions

MEDICAL POLICY EFFECTIVE DATE: 08/15/13 REVISED DATE: 07/17/14 SUBJECT: SPINAL INJECTIONS (EPIDURAL AND FACET INJECTIONS) FOR PAIN MANAGEMENT

Facet Joint Denervation. Description

Decompression of the Intervertebral Disc Using Laser Energy (Laser Discectomy) or Radiofrequency Coblation (Nucleoplasty)

MEDICAL POLICY MEDICAL POLICY DETAILS POLICY STATEMENT. Page: 1 of 5

Epidural Steroid Injections for Back Pain

RE: Washington State Health Care Authority 2018 Health Technology Topic Selection Sacroiliac Joint Fusion Surgery

Ultrasound and Fluoroscopic Paravertebral Facet Joint Injections

Bioimpedance Devices for Detection and Management of Lymphedema

ifuse implant system for treating chronic sacroiliac joint pain

National Imaging Associates, Inc. Clinical guidelines FACET JOINT INJECTIONS, MEDIAL BRANCH BLOCKS, AND FACET JOINT RADIOFREQUENCY NEUROTOMY

Clinical Policy: Caudal or Interlaminar Epidural Steroid Injections

Medical Policy. MP Epidural Steroid Injections for Neck or Back Pain

Topic: Percutaneous Axial Anterior Lumbar Fusion Date of Origin: June Section: Surgery Last Reviewed Date: June 2013

Re: Treatment Modalities for Facetogenic Pain, Policy #141

Radiofrequency Ablation of Peripheral Nerves to Treat Pain

Corporate Medical Policy

See Policy CPT/HCPCS CODE section below for any prior authorization requirements

Peripheral Subcutaneous Field Stimulation

Decompression of the Intervertebral Disc Using Laser Energy (Laser Discectomy) or Radiofrequency Coblation (Nucleoplasty)

Clinical Policy: Trigger Point Injections for Pain Management

Surgical Interruption of Pelvic Nerve Pathways for Primary and Secondary Dysmenorrhea

Medical technologies guidance Published: 2 October 2018 nice.org.uk/guidance/mtg39

Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

EPIDURAL STEROID AND FACET INJECTIONS FOR SPINAL PAIN

NEUROABLATION FOR TREATMENT OF CHRONIC PAIN

Policy Specific Section:

Clinical Policy: Selective Nerve Root Blocks and Transforaminal Epidural Steroid Injections

Transcription:

Surgical Treatment for Sacroiliac Joint Pain Policy Number: 6.01.23 Last Review: 5/2014 Origination: 5/2013 Next Review: 5/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide coverage for surgical treatment of sacroiliac joint. This is considered investigational. When Policy Topic is covered Not Applicable When Policy Topic is not covered Fusion/stabilization of the sacroiliac joint for the treatment of back pain presumed to originate from the SI joint is considered investigational, including but not limited to percutaneous and minimally invasive techniques. Radiofrequency ablation of the sacroiliac joint is considered investigational. Description of Procedure or Service Sacroiliac joint arthrography using fluoroscopic guidance with injection of an anesthetic has been explored as a diagnostic test for sacroiliac joint pain. Duplication of the patient s pain pattern with the injection of contrast medium suggests a sacroiliac etiology, as does relief of chronic back pain with injection of local anesthetic. Treatment of sacroiliac joint pain with corticosteroids, radiofrequency ablation, stabilization, or minimally invasive arthrodesis has also been explored. Background Similar to other structures in the spine, it is assumed that the sacroiliac joint may be a source of low back pain. In fact, prior to 1928, the sacroiliac joint was thought to be the most common cause of sciatica. In 1928, the role of the intervertebral disc was elucidated, and from that point forward, the sacroiliac joint received less research attention. Research into sacroiliac joint pain has been thwarted by any criterion standard to measure its prevalence and against which various clinical examinations can be validated. For example, sacroiliac joint pain is typically without any consistent, demonstrable radiographic or laboratory features and most commonly exists in the setting of morphologically normal joints. Clinical tests for sacroiliac joint pain may include various movement tests, palpation to detect tenderness, and pain descriptions by the patient. Further confounding study of the sacroiliac joint is that multiple structures, such as posterior facet joints and lumbar discs, may refer pain to the area surrounding the sacroiliac joint. Treatments being investigated for sacroiliac joint pain include prolotherapy, corticosteroid injection, radiofrequency ablation, stabilization, and arthrodesis. Regulatory Status A number of radiofrequency generators and probes have been cleared for marketing through the U.S. Food and Drug Administration s (FDA) 510(k) process. One device, the SInergy by Kimberly Clark/Baylis, is a water-cooled single-use probe that received FDA clearance in 2005, listing the Baylis

Pain Management Probe as a predicate device. The intended use is in conjunction with a radiofrequency generator to create radiofrequency lesions in nervous tissue. Several percutaneous or minimally invasive fixation/fusion devices have received marketing clearance by the FDA. These include the SI-FIX Sacroiliac Joint Fusion System (Medtronic), the IFUSE Implant System (SI Bone), the SImmetry Sacroiliac Joint Fusion System (Zyga Technologies) and the SI-LOK (Globus Medical). Rationale Treatment Hansen et al. published an updated systematic review of sacroiliac joint interventions in 2012. (12) The primary outcome was short-term (<6 months) or long-term (>6 months) pain relief. Evidence was classified as good, fair, or limited/poor based on the quality of evidence. A total of 11 studies (6 randomized and 5 non-randomized) met inclusion criteria. Review found that evidence for intra-articular steroid injections is limited/poor, as is the evidence for peri-articular injections (local anesthetic and steroid or botulinum toxin). For radiofrequency neurotomy, the evidence for cooled radiofrequency was found to be fair (2 randomized controlled trials [RCTs]), while evidence for conventional radiofrequency or pulsed radiofrequency was limited/poor. Radiofrequency Denervation Aydin et al. published a meta-analysis of radiofrequency ablation (RFA) for sacroiliac pain in 2010. (16) Nine studies were included that reported the primary outcome measure of a reduction of pain of 50% or greater, including 1 randomized placebo controlled study, 3 prospective observational studies, and 5 retrospective studies. All of the studies used injection of local anesthetic to determine if RFA was indicated for the patient. Seven studies reported follow-up to 3 months, and 6 studies reported follow-up to 6 months. Meta-analysis indicated that half or greater of the patients who received RFA to the sacroiliac joint showed a reduction in their pain of 50% or more at 3 and 6 months. Analysis found no evidence of publication bias, but heterogeneity in studies was observed for the 6-month follow-up. This systematic review is limited by the low quality of included studies and lack of RCTs. In addition, as noted by the authors, no standards have been established for the specific nerves to ablate or type of technique. Two small RCTs were identified for this literature review. The first was published in 2008 and was the single RCT included in the systematic review. This study examined the effect of lateral branch radiofrequency denervation with a cooled probe in 28 patients with injection-diagnosed sacroiliac joint pain. (17) Two of 14 patients (14%) in the placebo-control group reported pain relief at 1-month followup. None reported benefit at 3-month follow-up. Of the 14 patients treated with radiofrequency denervation, 11 (79%) reported pain relief at 1 month, 9 (64%) at 3 months, and 8 (57%) at 6 months. In 2012, Patel et al. reported a randomized double-blind placebo-controlled trial of lateral branch neurotomy with a cooled radiofrequency probe. (18) Fifty-one patients who had a positive response to 2 lateral branch blocks were randomized in a 2:1 ratio to lateral branch radiofrequency or sham. At 3- month follow-up, significant improvements in pain (-2.4 vs. -0.8), physical function (14 vs. 3), disability (- 11 vs. 2), and quality of life (0.09 vs. 0.02) were observed for radiofrequency treatment compared to controls (all respectively). With treatment success defined as a 50% or greater reduction in the numerical rating scale (NRS), 47% of radiofrequency-treated patients and 12% of sham patients achieved treatment success. The treatment response was durable out to 9 months. Arthrodesis The literature on arthrodesis (open or minimally invasive) for sacroiliac joint pain consists of case series. No randomized trials were identified. In 2010, Ashman et al. conducted a systematic review to compare fusion vs. denervation for chronic sacroiliac pain. (19) Six articles on fusion (95 patients) and 5 on denervation (68 patients) were included in the review. All studies on fusion were case series evaluating a single treatment. There were

2 small RCTs on radiofrequency denervation; one is described above, (17), and the other had only 9 patients. The strength of the evidence was considered to be very low to low, preventing conclusions regarding the comparative efficacy of the treatments. In 2008, Wise and Dall reported a small prospective series of 13 consecutive patients (19 joints) with sacroiliac joint pain diagnosed by a single block and treated with percutaneously inserted fusion cages filled with bone morphogenetic protein (Medtronic). (20) At 6-month follow-up, radiographs showed a fusion rate of 89% (17/19). At 24-month follow-up, there were significant improvements in VAS for back pain (improvement of 4.9 out of 10), leg pain ( 2.4) and dyspareunia (2.6). Two series were reported in 2012 on the ifuse Implant System for minimally-invasive fusion of the sacroiliac joint. A study by Sachs and Capobianco reported mean VAS for pain of 7.9 at baseline and 2.3 at 12-month follow-up for a series of 11 consecutive patients. (21) Rudolf reported a retrospective analysis of his first 50 consecutive patients. (22) There were 10 peri-operative complications, including implant penetration into the sacral neural foramen (2 patients) and compression of the L5 nerve (1 patient); these resolved with surgical retraction of the implant. At a minimum of 24 months follow-up (mean of 40 months), the treating surgeon was able to contact 45 patients. The mean pain score was 2, and 82% of patients had attained the minimum clinically important difference (MCID, defined as >2 out of 10). Clinical Input Received through Physician Specialty Societies and Academic Medical Centers While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted. In response to requests, input was received from 4 physician specialty societies (6 responses) and 3 academic medical centers (5 responses) while this policy was under review in 2010. Clinical input was mixed. There was general agreement that the evidence for sacroiliac joint injections is limited, although a majority of reviewers considered sacroiliac injections to be the best available approach for diagnosis and treatment in defined situations. Summary There is limited prospective or controlled evidence for sacroiliac joint arthrography, injection therapy, radiofrequency ablation (RFA) or fixation/fusion. For radiofrequency ablation, there are two small RCTs that report short-term benefit, but these are insufficient to determine the overall effect on health outcomes. Further high-quality controlled trials are needed that compare specific procedures in defined populations to placebo and to alternative treatments. Case series are inadequate evidence due to the variable natural history of back pain, the presence of confounders of outcome, and the potential for a placebo effect. In general, the literature regarding injection therapy on joints in the back is of poor quality. The current evidence on sacroiliac joint arthrography, injections, RFA, and fixation/fusion is insufficient to permit conclusions regarding the effect of these procedures on health outcomes. Therefore, these techniques are considered investigational for the diagnosis and treatment of sacroiliac joint pain. Practice Guidelines and Position Statements The ASIPP Interventional Pain Management guidelines were updated in 2009. The guidelines for diagnostic and therapeutic sacroiliac joint injections were based on the systematic review by Manchikanti et al. and Rupert et al. described earlier. (6, 7) Evidence for sacroiliac joint injections was considered to be level II-2 (evidence obtained from at least 1 properly designed small diagnostic accuracy study). The guidelines indicate that sacroiliac joint blocks appear to be the evaluation of choice to provide appropriate diagnosis, due to the inability to make the diagnosis of sacroiliac jointmediated pain with non-invasive tests. Evidence was determined to be unavailable to establish efficacy of intra-articular sacroiliac joint injections for therapeutic purposes.

Common indications for sacroiliac joint injections were listed as follows: Somatic or nonradicular low back and lower extremity pain below the level of L5 vertebra. Duration of pain of at least 3 months. Average pain levels of >6 on a scale of 0 to 10. Intermittent or continuous pain causing functional disability. Failure to respond to more conservative management, including physical therapy modalities with exercises, chiropractic management, and non-steroidal anti-inflammatory agents. Lack of obvious evidence for disc-related or facet joint pain. No contraindications with understanding of consent, nature of the procedure, needle placement, or sedation. No history of allergy to contrast administration, local anesthetics, steroids, Sarapin, or other drugs potentially utilized. Contraindications or inability to undergo physical therapy, chiropractic management, or inability to tolerate non-steroidal anti-inflammatory drugs. For therapeutic sacroiliac joint interventions with intra-articular injections or radiofrequency neurotomy, the joint should have been positive utilizing controlled diagnostic blocks. Recommended frequency of interventions was also described. The 2009 practice guidelines from the APS were based on a systematic review that was commissioned by the APS and conducted at the Oregon Evidence-Based Practice Center. (8, 9) The APS guideline states that there is insufficient evidence to evaluate validity or utility of diagnostic sacroiliac joint block as a diagnostic procedure for low back pain with or without radiculopathy and that there is insufficient evidence to adequately evaluate benefits of sacroiliac joint steroid injection for nonradicular low back pain. Medicare National Coverage There is no national coverage determination. References: 1. Dreyfuss P, Michaelsen M, Pauza K et al. The value of medical history and physical examination in diagnosing sacroiliac joint pain. Spine (Phila Pa 1976) 1996; 21(22):2594-602. 2. Schwarzer AC, Aprill CN, Bogduk N. The sacroiliac joint in chronic low back pain. Spine (Phila Pa 1976) 1995; 20(1):31-7. 3. Maigne JY, Aivaliklis A, Pfefer F. Results of sacroiliac joint double block and value of sacroiliac pain provocation tests in 54 patients with low back pain. Spine (Phila Pa 1976) 1996; 21(16):1889-92. 4. Boswell MV, Trescot AM, Datta S et al. Interventional techniques: evidence-based practice guidelines in the management of chronic spinal pain. Pain Physician 2007; 10(1):7-111. 5. Hansen HC, McKenzie-Brown AM, Cohen SP et al. Sacroiliac joint interventions: a systematic review. Pain Physician 2007; 10(1):165-84. 6. Manchikanti L, Boswell MV, Singh V et al. Comprehensive evidence-based guidelines for interventional techniques in the management of chronic spinal pain. Pain Physician 2009; 12(4):699-802. 7. Rupert MP, Lee M, Manchikanti L et al. Evaluation of sacroiliac joint interventions: a systematic appraisal of the literature. Pain Physician 2009; 12(2):399-418. 8. Chou R, Atlas SJ, Stanos SP et al. Nonsurgical interventional therapies for low back pain: a review of the evidence for an American Pain Society clinical practice guideline. Spine (Phila Pa 1976) 2009; 34(10):1078-93. 9. Chou R, Loeser JD, Owens DK et al. Interventional therapies, surgery, and interdisciplinary rehabilitation for low back pain: an evidence-based clinical practice guideline from the American Pain Society. Spine (Phila Pa 1976) 2009; 34(10):1066-77. 10. Manchikanti L, Datta S, Derby R et al. A critical review of the American Pain Society clinical practice guidelines for interventional techniques: part 1. Diagnostic interventions. Pain Physician 2010; 13(3):E141-74.

11. Manchikanti L, Datta S, Gupta S et al. A critical review of the American Pain Society clinical practice guidelines for interventional techniques: part 2. Therapeutic interventions. Pain Physician 2010; 13(4):E215-64. 12. Hansen H, Manchikanti L, Simopoulos TT et al. A systematic evaluation of the therapeutic effectiveness of sacroiliac joint interventions. Pain Physician 2012; 15(3):E247-78. 13. Kim WM, Lee HG, Jeong CW et al. A randomized controlled trial of intra-articular prolotherapy versus steroid injection for sacroiliac joint pain. J Altern Complement Med 2010; 16(12):1285-90. 14. Weksler N, Velan GJ, Semionov M et al. The role of sacroiliac joint dysfunction in the genesis of low back pain: the obvious is not always right. Arch Orthop Trauma Surg 2007; 127(10):885-8. 15. Murakami E, Tanaka Y, Aizawa T et al. Effect of periarticular and intraarticular lidocaine injections for sacroiliac joint pain: prospective comparative study. J Orthop Sci 2007; 12(3):274-80. 16. Aydin SM, Gharibo CG, Mehnert M et al. The role of radiofrequency ablation for sacroiliac joint pain: a meta-analysis. PM R 2010; 2(9):842-51. 17. Cohen SP, Hurley RW, Buckenmaier CC, 3rd et al. Randomized placebo-controlled study evaluating lateral branch radiofrequency denervation for sacroiliac joint pain. Anesthesiology 2008; 109(2):279-88. 18. Patel N, Gross A, Brown L et al. A randomized, placebo-controlled study to assess the efficacy of lateral branch neurotomy for chronic sacroiliac joint pain. Pain Med 2012; 13(3):383-98. 19. Ashman B, Norvell DC, Hermsmeyer JT. Chronic sacroiliac joint pain: fusion versus denervation as treatment options. Evid Based Spine Care J 2010; 1(3):35-44. 20. Wise CL, Dall BE. Minimally invasive sacroiliac arthrodesis: outcomes of a new technique. J Spinal Disord Tech 2008; 21(8):579-84. 21. Sachs D, Capobianco R. One year successful outcomes for novel sacroiliac joint arthrodesis system. Ann Surg Innov Res 2012; 6(1):13. 22. Rudolf L. Sacroiliac Joint Arthrodesis-MIS Technique with Titanium Implants: Report of the First 50 Patients and Outcomes. Open Orthop J 2012; 6:495-502. Billing Coding/Physician Documentation Information 27280 Arthrodesis, sacroiliac joint (including obtaining graft) 0334T Sacroiliac joint stabilization for arthrodesis, percutaneous or minimally invasive (indirect visualization), includes obtaining and applying autograft or allograft (structural or morselized), when performed, includes image guidance when performed (eg, CT or fluoroscopic). Effective 7/1/2013 There is no specific CPT code for radiofrequency ablation of the sacroiliac joint. Code 27299 unlisted procedure, pelvis or hip joint would likely be used. Additional Policy Key Words N/A Policy Implementation/Update Information 5/1/13 New policy; considered investigational. Policy statement regarding sacroiliac joint fusion included from previous policy 7.01.509 Sacroiliac Joint Fusion for the Treatment of Low Back Pain. 5/1/14 No policy statement changes. State and Federal mandates and health plan contract language, including specific provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The medical policies contained herein are for informational purposes. The medical policies do not constitute medical advice or medical care. Treating health care providers are independent contractors and are neither employees nor agents Blue KC and are solely responsible for diagnosis, treatment and medical advice. No part of this publication may be reproduced, stored in a

retrieval system or transmitted, in any form or by any means, electronic, photocopying, or otherwise, without permission from Blue KC.